Clustered tDCS Sessions for Reducing Alcohol Consumption in Non-abstinent Patients With Alcohol Use Disorder

Summary

The global burden of disease and injury attributable to alcohol is considerable: worldwide, 5.3% of deaths are directly related to alcohol. In France, 41 000 deaths were attributable to alcohol in 2015. Alcohol can cause more than 200 diseases. There is an important social cost attached to alcohol, which is estimated at 120 billion euros in France in 2010.

There is a scientific and clinical rationale for promoting alcohol reduction in alcohol use disorder (AUD). Alcohol harm reduction strategies have consistently shown promising results. Reducing alcohol intake is an established treatment goal with significant impact on morbimortality and associated socio-economic burden. This is possible because it reduces direct alcohol damage, and because it represents an attractive goal for patients who are not interested in abstinence.

For alcohol consumption reduction, two pharmacological agents are currently available on the market: nalmefene and baclofen. Nalmefene's approved indication is the "reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification." The therapeutic effects of nalmefene on alcohol consumption reduction remain modest: a recent metaanalysis of pharmacological treatments for alcohol use disorder found no effect on the number of heavy drinking days (RR 0.74; 95% CI \[0.44-1.15\]) (Bahji 2022). In addition, adverse events such as nausea, vomiting, dizziness, sleep disturbances, and decreased appetite are commonly reported (van den Brink 2014). A recent Cochrane review reported a very modest effect of baclofen on the number of abstinent days (mean difference 9.07%; 95% CI \[3.30 to 14.85\]) and no significant effect on the number of heavy drinking days (SMD -0.18; 95% CI \[-0.48 to 0.11\]) or on the number of drinks per day (mean difference -0.45; 95% CI \[-1.20 to 0.30\]) (Agabio 2023). Moreover, the use of baclofen requires cautious and gradual dose titration due to frequent adverse effects, particularly sedation, dizziness, and vigilance disturbances, which may limit its tolerability and adherence in clinical practice.

Given that currently available treatment options for alcohol consumption reduction display suboptimal efficacy and tolerability profiles, other approaches, such as neuromodulation interventions for alcohol use disorder, are currently under investigation.

Transcranial direct current stimulation (tDCS) is a non-invasive and safe cortical excitability modulation method. It involves passing a weak direct current through the brain between two electrodes, anode and cathode.

Anodal tDCS has been shown to improve numerous cognitive processes, and it has been hypothesized that anodal tDCS enhances executive function and improves cognitive control in AUD, reducing the probability of relapse. Current evidence allows for the formulation of a Level B recommendation (probable efficacy) of repeated tDCS in fibromyalgia, major depressive episodes and addiction. This recommendation was formulated for a specific electrode montage with anode over the right dorsolateral prefrontal cortex (DLPFC) and cathode over the left DLPFC.

Overall, the results of the REDSTIM trial are encouraging, with statistically significant effects in favor of active stimulation compared with sham. However, the magnitude of the clinical effects remains limited, as the reduction in alcohol consumption appears modest.

Since the initiation of the REDSTIM protocol in 2014, intensified tDCS protocols have been investigated in psychiatry and neurology, including so-called "clustered" designs. The principle of clustered tDCS relies on the repeated, sequential administration of acute phases of tDCS treatment.

In line with this approach, REDSTIM 2 will reproduce the same technical characteristics as REDSTIM, with the exception of the tDCS administration schedule. In the present protocol, three series (clusters) of 10 sessions will be delivered over a 12-week period, with each treatment cluster separated by a three-week interval. We hypothesize that this clustered design will increase the clinical potential of the original tDCS protocol.

The decision to intensify the REDSTIM protocol through repeated tDCS clusters is based on the following considerations:

* From a neuroscientific perspective
* From a clinical perspective
* From the patient perspective
* From the research team perspective In REDSTIM 2, tDCS treatment clusters will be repeated across three phases over a 12-week period, representing a significant intensification of the REDSTIM protocol while remaining compatible with participant constraints and safety, and while potentially improving adherence to the protocol.

Conditions

• Chronic Alcohol Use Disorder

Interventions

DEVICE

Active tDCS

clustered 5-day active tDCS (10 sessions, 2 sessions per day, 2 mA) every 4 weeks during 12 consecutive weeks

DEVICE

Placebo tDCS

clustered 5-day sham tDCS (10 sessions, 2 sessions per day, 0 mA) every 4 weeks during 12 consecutive weeks

Sponsors & Collaborators

• Centre Hospitalier Universitaire Dijon

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-04-30

Primary Completion

2029-10-31

Completion

2029-10-31

Countries

• France

Study Locations